Current Atherosclerosis Reports

, Volume 11, Issue 2, pp 81–83 | Cite as

Clinical trials report

  • John A. Farmer
Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smilde TJ, van Wissen S, Wollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577–581.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown BG, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008, 358:1504–1547.PubMedCrossRefGoogle Scholar
  3. 3.
    During A, Dawson HD, Harrison EH: Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 2005, 135:2305–2312.PubMedGoogle Scholar
  4. 4.
    Greenland P, Lloyd-Jones D: Critical lessons from the ENHANCE trial. JAMA 2008, 299:953–955.PubMedCrossRefGoogle Scholar
  5. 5.
    Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  • John A. Farmer

There are no affiliations available

Personalised recommendations